Lung Cancer

pre vii: Contents
pp. vii-vii(1)

pre viiii: Contents continued
pp. viii-viii(1)

Women's susceptibility to tobacco carcinogens
pp. 1-5(5)
Authors: Henschke C.I.; Miettinen O.S.

Population-based outcomes for small cell lung cancer: impact of standard management policies in British Columbia
pp. 7-16(10)
Authors: Laskin J.J.; Erridge S.C.; Coldman A.J.; D'yachkova Y.; Speers C.; Westeel V.; Hislop T.G.; Olivotto I.A.; Murray N.

Dexamethasone regulation of gastrin-releasing peptide receptor in human lung cells
pp. 17-28(12)
Authors: Novak J.; Schleman S.; Scott J.; Balderman V.L.; Krech L.; Kane M.A.

Lung cancer detection by a RT-nested PCR using MAGE A1-6 common primers
pp. 29-37(9)
Authors: Jheon S.; Hyun D.-S.; Lee S.-C.; Yoon G.-S.; Jeon C.-H.; Park J.-W.; Park C.-K.; Jung M.-H.; Lee K.-D.; Chang H.-K.

Clinical-radiological presentation and outcome of surgically treated pulmonary carcinoid tumours: a long-term single institution experience
pp. 39-45(7)
Authors: Schrevens L.; Vansteenkiste J.; Deneffe G.; De Leyn P.; Verbeken E.; Vandenberghe T.; Demedts M.

Association of macrophages, mast cells and eosinophil leukocytes with angiogenesis and tumor stage in non-small cell lung carcinomas (NSCLC)
pp. 47-54(8)
Authors: Tataroglu C.; Kargi A.; Ozkal S.; Esrefoglu N.; Akkoclu A.

Serum VEGF and bFGF adds prognostic information in patients with normal platelet counts when sampled before, during and after treatment for locally advanced non-small cell lung cancer
pp. 55-62(8)
Authors: Brattstrom D.; Bergqvist M.; Hesselius P.; Larsson A.; Wagenius G.; Brodin O.

Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma
pp. 63-69(7)
Authors: van Klaveren R.J.; Aerts J.G.J.V.; de Bruin H.; Giaccone G.; Manegold C.; van Meerbeeck J.P.

Inadequacy of the new Response Evaluation Criteria in Solid Tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases
pp. 71-74(4)
Authors: Monetti F.; Casanova S.; Grasso A.; Cafferata M.A.; Ardizzoni A.; Neumaier C.E.

Staging and evaluating responses in malignant pleural mesothelioma
pp. 75-76(2)
Author: Hillerdal G.

Photodynamic therapy for peripheral lung cancer
pp. 77-82(6)
Authors: Okunaka T.; Kato H.; Tsutsui H.; Ishizumi T.; Ichinose S.; Kuroiwa Y.

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial
pp. 83-91(9)
Authors: Paccagnella A.; Favaretto A.; Oniga F.; Barbieri F.; Ceresoli G.; Torri W.; Villa E.; Verusio C.; Cetto G.L.; Santo A.; De Pangher V.; Artioli F.; Cacciani G.C.; Parodi G.; Soresi F.; Ghi M.G.; Morabito A.; Biason R.; Giusto M.; Mosconi P.; Chiarion Sileni V.; GSTPV Gruppo di Studio Tumori Polmonari del Veneto

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908
pp. 93-100(8)
Authors: Katakami N.; Sugiura T.; Nogami T.; Yamamoto H.; Negoro S.; Nakano T.; Okamoto N.; Takada Y.; Kodama K.; Ariyoshi Y.

Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe
pp. 101-112(12)
Authors: Schiller J.; Tilden D.; Aristides M.; Lees M.; Kielhorn A.; Maniadakis N.; Bhalla S.

Taking ACTION to establish direct costs and outcomes of treating advanced non-small cell lung cancer in routine clinical practice
pp. 113-115(3)
Authors: Cullen M.; Szczepura A.; Thomas M.; Kielhorn A.

Reply to ''Radiation Pneumonitis and Docetaxel''
pp. 117-118(2)
Author: Senan S.

Reply to Dr. S. Senan
pp. 119-120(2)
Author: Onishi H.

Practical Chemotherapy: A Multidisciplinary Guide - Maxwell Summerhayes, Susanna Daniels (Eds.), Radcliffe Medical Press, Oxford, UK, 2003
pp. 121-121(1)
Author: Lassen U.